Serum tumor markers and PET/CT imaging for tumor recurrence detection
Loading...
Date
Authors
Kruse, Vibeke
Cocquyt, Veronique
Borms, Marleen
Maes, Alex
Van de Wiele, Christophe
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
When confronted with a suspicious rise in CA
15.3 in asymptomatic breast cancer patients following
primary treatment and negative or equivocal conventional
imaging findings, FDG PET/CT allows assessment of the
site and extent of the recurring disease with an accuracy
of 83 %. Both FDG PET and FDG PET/CT are superior
when compared to CT alone for the purpose of recurrence
detection in patients suffering from ovarian carcinoma
who have completed primary therapy but demonstrate a
rising serum CA-125 level. As the global accuracy of CT
alone for detection of recurrence of ovarian cancer
approximates 80 %, CT scan should be performed upfront
to identify the site of recurrence. When confronted with
negative or equivocal CT findings, FDG PET alone or
FDG PET/CT should be added. In patients with rising serum CEA levels that have undergone primary treatment
for a colorectal carcinoma, both FDG PET and FDG PET/
CT allow detection of tumor recurrence with an accuracy
of 95 %, well above that of CT and MRI. Available
studies further suggest that FDG/PET findings will affect
treatment management in 28–50 % of these patients. The
detection rate of both 11C-choline and 18F-choline PET
and PET/CT for local, regional, and distant recurrence in
prostate carcinoma patients with a biochemical recurrence
increases with rising PSA value at the time of imaging
and reaches about 75 % in patients with PSA[3 ng/mL.
Furthermore, PET and PET/CT with [11C]- and [18F]-
choline derivates may be helpful in the clinical setting for
optimization of individualized treatment.
Description
Keywords
Serum tumor markers, FDG PET/CT, Tumor recurrence, PET/CT, Breast cancer, Ovarian cancer, Colorectal cancer, Prostate carcinoma, Positron emission tomography (PET), Computerized tomography' (CT), Fluorine-18-Fluorodeoxyglucose (FDG)
Sustainable Development Goals
Citation
Kruse, V, Cocquyt, V, Borms, M, Maes, A & Van de Wiele, C 2013, 'Serum tumor markers and PET/CT imaging for tumor recurrence detection', vol. 27, no. 2, pp. 97-104.